Contents

Abbreviations *xix*

Part I Fundamentals of Cellular and Molecular Biology *1*

1 The Cell as the Basic Unit of Life *3*
Michael Wink
References *8*
Further Reading *8*

2 Structure and Function of Cellular Macromolecules *9*
Michael Wink
2.1 Structure and Function of Sugars *9*
2.2 Structure of Membrane Lipids *13*
2.3 Structure and Function of Proteins *17*
2.4 Structure of Nucleotides and Nucleic Acids (DNA and RNA) *25*
References *32*
Further Reading *32*

3 Structure and Functions of a Cell *33*
Michael Wink
3.1 Structure of a Eukaryotic Cell *33*
3.1.1 Structure and Function of the Cytoplasmic Membrane *33*
3.1.1.1 Membrane Permeability *33*
3.1.1.2 Transport Processes Across Biomembranes *34*
3.1.1.3 Receptors and Signal Transduction at Biomembranes *37*
3.1.2 Endomembrane System in a Eukaryotic Cell *40*
3.1.3 Mitochondria and Chloroplasts *45*
3.1.4 Cytoplasm *49*
3.1.5 Cytoskeleton *53*
3.1.6 Cell Walls *53*
3.2 Structure of Bacteria *53*
3.3 Structure of Viruses *55*
3.4 Differentiation of Cells *56*
3.5 Cell Death *60*
References *61*
Further Reading *61*

4 Biosynthesis and Function of Macromolecules (DNA, RNA, and Proteins) *63*
Michael Wink
4.1 Genomes, Chromosomes, and Replication *63*
4.1.1 Genome Size *63*

Bibliografische Informationen
http://d-nb.info/1182714668

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

4.1.2 Composition and Function of Chromosomes *67*
4.1.3 Mitosis and Meiosis *69*
4.1.4 Replication *71*
4.1.5 Mutations and Repair Mechanisms *72*
4.2 Transcription: From Gene to Protein *77*
4.3 Protein Biosynthesis (Translation) *81*
Further Reading *85*

5 Distributing Proteins in the Cell (Protein Sorting) *87*
Michael Wink
5.1 Import and Export of Proteins via the Nuclear Pore *87*
5.2 Import of Proteins in Mitochondria, Chloroplasts, and Peroxisomes *88*
5.3 Protein Transport into the Endoplasmic Reticulum *89*
5.4 Vesicle Transport from the ER via the Golgi Apparatus to the Cytoplasmic Membrane *92*
References *94*
Further Reading *94*

6 Evolution and Diversity of Organisms *95*
Michael Wink
6.1 Prokaryotes *95*
6.2 Eukaryotes *95*
References *101*
Further Reading *101*

Part II Standard Methods in Molecular Biotechnology *103*

7 Isolation and Purification of Proteins *105*
Thomas Wieland
7.1 Introduction *105*
7.2 Producing a Protein Extract *106*
7.3 Gel Electrophoretic Separation Methods *107*
7.3.1 Principles of Electrophoresis *107*
7.3.2 Native Gel Electrophoresis *107*
7.3.3 Discontinuous Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) *107*
7.3.4 Two-Dimensional (2D) Gel Electrophoresis and Isoelectric Focusing (IEF) *108*
7.3.5 Detecting Proteins in Gels *108*
7.4 Methods of Protein Precipitation *109*
7.5 Column Chromatography Methods *109*
7.5.1 General Principles of Separation *109*
7.5.1.1 Size Exclusion Chromatography (Gel Filtration) *109*
7.5.1.2 Hydrophobic Interaction Chromatography *111*
7.5.1.3 Ion Exchange Chromatography *111*
7.5.1.4 Hydroxyapatite Chromatography *112*
7.5.2 Group-Specific Separation Techniques *112*
7.5.2.1 Chromatography on Protein A or Protein G *112*
7.5.2.2 Chromatography on Cibacron Blue (Blue Gel) *112*
7.5.2.3 Chromatography on Lectins *112*
7.5.2.4 Chromatography on Heparin *113*
7.5.3 Purification of Recombinant Fusion Proteins *113*
7.5.3.1 Chromatography on Chelating Agents *113*
7.5.3.2 Chromatography on Glutathione Matrices *114*

7.6 Examples *114*
7.6.1 Example 1: Purification of Nucleoside Diphosphate Kinase from the Cytosol of Bovine Retina Rod Cells *114*
7.6.2 Example 2: Purification of Recombinant His_6-RGS16 After Expression in *E. coli* *114*
Further Reading *115*

8 Mass Spectrometry and Applications in Proteomics and Microbial Identification *117*
Andreas Schlosser and Wolf D. Lehmann
8.1 Principles of ESI and MALDI Mass Spectrometry *117*
8.2 Instrumental Setup *118*
8.3 Intact Protein Analysis *119*
8.3.1 Protein Digestion *119*
8.3.2 Peptide Fragmentation *119*
8.3.3 Protein Identification with MS/MS Spectra *121*
8.4 Protein and Proteome Quantification *121*
8.4.1 Label-Free Quantification *121*
8.4.2 Chemical Stable Isotope Labeling *121*
8.4.3 Metabolic Stable Isotope Labeling *122*
8.5 Protein–Protein Interaction Analysis *123*
8.6 Analysis of Posttranslational Modifications *124*
8.7 Microbial Identification and Resistance Detection *125*
References *126*

9 Isolation of DNA and RNA *129*
Hans Weiher
9.1 Introduction *129*
9.2 DNA Isolation *129*
9.3 RNA Isolation *131*
9.3.1 Enrichment of mRNA *131*
Reference *131*

10 Chromatography and Electrophoresis of Nucleic Acids *133*
Hans Weiher
10.1 Introduction *133*
10.2 Chromatographic Separation of Nucleic Acids *133*
10.3 Electrophoresis *134*
10.3.1 Agarose Gel Electrophoresis: Submarine Electrophoresis *134*
10.3.2 Pulsed-Field Agarose Gel Electrophoresis *134*
10.3.3 Polyacrylamide Gel Electrophoresis (PAGE) *135*
Further Reading *135*

11 Hybridization of Nucleic Acids *137*
Hans Weiher
11.1 Significance of Base Pairing *137*
11.2 Experimental Hybridization: Kinetic and Thermodynamic Control *137*
11.3 Analytical Techniques *138*
11.3.1 Clone Detection, Southern Blotting, Northern Blotting, and Gene Diagnosis *138*
11.3.2 Systematic Gene Diagnosis and Expression Screening Based on Gene Arrays *139*
11.3.3 *In Situ* Hybridization *139*
References *140*
Further Reading *140*

12 Use of Enzymes in the Modification of Nucleic Acids *141*
Ingrid Herr and Michael Wink
12.1 Restriction Enzymes (Restriction Endonucleases) *141*
12.2 Ligases *142*
12.3 Methyltransferases *142*
12.4 DNA Polymerases *143*
12.5 RNA Polymerases and Reverse Transcriptase *144*
12.6 Nucleases *144*
12.7 T4 Polynucleotide Kinase *144*
12.8 Phosphatases *145*
Further Reading *145*

13 Polymerase Chain Reaction *147*
Richard Jäger and Hans Weiher
13.1 Introduction *147*
13.2 PCR Methods *147*
13.2.1 Basic Principle *147*
13.2.2 Primer Design and Hot Start PCR *148*
13.2.3 Multiplex PCR *149*
13.2.4 RT-PCR *149*
13.2.5 Qualitative Analysis of the PCR Products *149*
13.3 PCR as a Quantitative Method *149*
13.3.1 PCR Phases and PCR Efficiency *149*
13.3.2 Quantitative Real-Time PCR *150*
13.3.3 Digital PCR *151*
13.4 Areas of Application *151*
13.4.1 Genome Analysis *151*
13.4.2 Cloning Techniques *152*
13.4.3 Gene Expression Studies *152*
Further Reading *152*

14 DNA Sequencing *153*
Richard Jäger and Hans Weiher
14.1 Introduction *153*
14.2 The Sanger Method *153*
14.3 Pyrosequencing *154*
14.4 Second-Generation Sequencing: Illumina and Ion Torrent *155*
14.4.1 Overview *155*
14.4.2 The Illumina Sequencing System *155*
14.4.3 The Ion Torrent Sequencing System *156*
14.5 Third-Generation Sequencing Techniques *156*
14.5.1 Overview *156*
14.5.2 SMRT Sequencing *157*
14.5.3 Nanopore Sequencing *157*
14.6 The Impact of the DNA Sequencing Technology *158*
References *158*
Further Reading *158*
Websites *158*

15 Cloning Procedures *159*
Thomas Wieland and Susanne Lutz
15.1 Introduction *159*
15.2 Construction of Recombinant Vectors *159*
15.2.1 Insert *159*

15.2.2 Vector *161*
15.2.3 Essential Components of Vectors *162*
15.2.3.1 Bacterial Origin of Replication (*ori*) *162*
15.2.3.2 Antibiotic Resistance *162*
15.2.3.3 Polylinkers *162*
15.2.4 Cloning Using Recombination Systems *162*
15.2.5 Further Components of Vectors for Prokaryotic Expression Systems *163*
15.2.5.1 Promoter *163*
15.2.5.2 Ribosome-Binding Site *163*
15.2.5.3 Termination Sequence *164*
15.2.5.4 Fusion Sequence *164*
15.2.6 Further Components of Eukaryotic Expression Vectors *164*
15.2.6.1 Eukaryotic Expression Vectors: Yeast *164*
15.2.6.2 Eukaryotic Expression Vectors for Mammal Cells *165*
15.2.6.3 Viral Expression Systems for Mammalian Cells *167*
15.2.7 Nonviral Introduction of Heterologous DNA to Host Organisms (Transformation, Transfection) *168*
15.2.7.1 Transformation of Prokaryotes *168*
15.2.7.2 Transformation of Yeast Cells *169*
15.2.7.3 Transfection of Mammal Cells *169*
Further Reading *170*

16 Expression of Recombinant Proteins *171*
Thomas Wieland
16.1 Introduction *171*
16.2 Expression of Recombinant Proteins in Host Organisms *171*
16.2.1 Expression in *E. coli* *172*
16.2.2 Expression in Yeasts *175*
16.2.3 Expression in Insect Cells *177*
16.2.3.1 Expression Based on Recombinant Baculoviruses *177*
16.2.3.2 Expression of Proteins in Stably Transfected Insect Cells *178*
16.2.4 Expression of Proteins in Mammalian Cells *178*
16.3 Expression in Cell-Free Systems *179*
16.3.1 Expression of Proteins in Reticulocyte Lysates *180*
16.3.2 Protein Expression Using *E. coli* Extracts *180*
Further Reading *180*

17 Patch Clamp Method *181*
Robert Kraft
17.1 Ion Channels *181*
17.2 Technical Requirements of the Patch Clamp Method *181*
17.3 Patch Clamp Configurations *182*
17.4 Applications of the Patch Clamp Method *183*
Reference *185*
Further Reading *185*

18 Cell Cycle Analysis *187*
Stefan Wölfl
18.1 Introduction *187*
18.2 Analyzing the Cell Cycle *187*
18.3 Experimental Analysis of the Cell Cycle *189*
18.3.1 Preparing Synchronized Cell Cultures of S. cerevisiae *189*
18.3.1.1 Centrifugal Elutriation *190*
18.3.1.2 Cell Cycle Arrest Using α-Factor *190*
18.3.2 Identification of Cell Cycle Stages *191*

18.3.2.1 Budding Index *191*
18.3.2.2 Fluorescent Staining of the Nucleus *191*
18.3.2.3 Detection of Cell Cycle Phases Using Fluorescent Proteins as Reporters *194*
Acknowledgments *195*
Further Reading *196*

19 Microscopic Techniques *197*
Stephan Diekmann
19.1 Introduction *197*
19.2 Electron Microscopy *197*
19.2.1 Cryo-electron Microscopy *199*
19.2.2 Electron Tomography *199*
19.3 Atomic or Scanning Force Microscopy *199*
19.3.1 Force Spectroscopy *200*
19.3.2 Advantages and Disadvantages *201*
19.4 Light Microscopy *201*
19.4.1 Deconvolution *202*
19.4.2 Confocal Microscopy *202*
19.4.3 Why Fluorescence? *203*
19.4.4 Nanoscopy *203*
19.5 Microscopy in the Living Cell *204*
19.5.1 Analysis of Fluorescently Labeled Proteins *In Vivo* *205*
19.5.2 Fluorescence Recovery After Photobleaching *206*
19.5.3 Fluorescence Correlation Spectroscopy *206*
19.5.4 Förster Resonance Energy Transfer and Fluorescence Lifetime Imaging Microscopy *207*
19.5.5 Single-Molecule Fluorescence *207*
Further Reading *207*

20 Laser Applications *209*
Rainer Fink
20.1 Laser Development: A Historical Perspective *209*
20.2 Types of Lasers and Setups *210*
20.3 Properties of Laser Radiation *210*
20.4 Applications *211*
20.4.1 Laser Scanning Microscopy *211*
20.4.2 Optical Tweezers *212*
20.4.3 Laser Microdissection and Laser Therapy *212*
20.4.4 Manufacturing of Products in Medical Technology and Biotechnology Products *213*
Further Reading *213*

Part III Key Topics *215*

21 Sequencing the Universe of Life *217*
Stefan Wiemann
21.1 What to Sequence? *217*
21.1.1 Whole-Genome Sequencing *217*
21.1.2 Exome Sequencing *220*
21.1.3 (Gene) Panel Sequencing *220*
21.1.4 RNA Sequencing *221*
21.1.4.1 Tag- vs. Full-Length Sequencing *221*
21.1.4.2 Sequencing of RNA Species and Modifications *221*
21.1.4.3 Sequencing of Single Cells *222*

21.1.4.4 *In Situ* Sequencing *222*
21.1.5 (Whole-Genome) Bisulfite Sequencing of DNA *223*
21.1.6 Sequencing to Characterize Chromatin Structure and Beyond *223*
21.2 Sequencing Projects: Human *224*
21.2.1 Initial Sequencing of the Human Genome *224*
21.2.2 The 1000 Genomes Project: Assessing Natural Variation *224*
21.2.3 Screening for Genetic Disease *225*
21.2.4 Sequencing of Populations *226*
21.2.5 TCGA and ICGC: Screening for Cancer Driver Mutations *226*
21.3 Sequencing Other Species, Environments, ... *228*
21.4 Sequencing in the Clinics: Personalizing Oncology *228*
21.5 Sequencing in the Private Sector: Direct to Consumer Testing (DTC) *231*
21.6 The Information Content of a Genome Sequence and Ethical Consequences *231*
References *232*

22 Cellular Systems Biology *239*
Melanie Boerries, Hauke Busch, and Rainer König
22.1 Introduction *239*
22.2 Analysis of Cellular Networks by Top-Down Approaches *240*
22.2.1 Motivation *240*
22.2.2 Definitions and Construction of the Networks *240*
22.2.3 Gene Set Enrichment Tests *241*
22.2.4 Inferring Gene Regulators Employing Gene Regulatory Models *242*
22.2.5 Network Descriptors *243*
22.2.5.1 Scale-Free Networks *243*
22.2.5.2 Centrality *243*
22.2.5.3 The Clustering Coefficient *244*
22.2.6 Detecting Essential Enzymes with a Machine Learning Approach *244*
22.2.7 Elementary Flux Modes *244*
22.3 Overview over Bottom-Up Modeling of Biochemical Networks *247*
22.3.1 Motivation *247*
22.3.2 Choosing Model Complexity and Model Building *248*
22.3.3 Model Simulation *251*
22.3.4 Model Calibration *252*
22.3.5 Model Verification and Analysis *254*
22.3.6 Examples *254*
Further Reading *258*
References *259*

23 Protein–Protein and Protein–DNA Interactions *261*
Peter Uetz and Ehmke Pohl
23.1 Protein–Protein Interactions *261*
23.1.1 Classification and Specificity: Protein Domains *261*
23.1.2 Protein Networks and Complexes *262*
23.1.3 Structural Properties of Interacting Proteins *262*
23.1.4 Which Forces Mediate Protein–Protein Interactions? *263*
23.1.4.1 Thermodynamics *264*
23.1.4.2 Energetics *264*
23.1.5 Methods to Examine Protein–Protein Interactions *264*
23.1.6 Theoretical Prediction of Protein–Protein Interactions *266*
23.1.7 Regulation of Protein–Protein Interactions *266*
23.1.8 Biotechnological and Medical Applications of Protein–Protein Interactions *268*
23.2 Protein–DNA Interactions *269*
23.2.1 Specific Protein–DNA Interaction *269*

23.2.2 Thermodynamic Consideration *270*
23.2.3 Methods to Study Protein–DNA Interactions *270*
23.2.3.1 Structural Classification of Protein–DNA Complexes *270*
23.2.4 Regulatory Networks and System Biology *270*
23.2.5 Medical Importance of Protein–DNA Interactions *273*
23.2.6 Biotechnological Applications *274*
References *275*
Further Reading *275*

24 Bioinformatics *277*
Benedikt Brors
24.1 Introduction *277*
24.2 Data Sources *277*
24.2.1 Primary Databases: EMBL/GenBank/DDBJ, PIR, and Swiss-Prot *277*
24.2.2 Genome Databases: Ensembl and GoldenPath *278*
24.2.3 Motif Databases: BLOCKS, PROSITE, Pfam, ProDom, and SMART *278*
24.2.4 Molecular Structure Databases: PDB and SCOP *278*
24.2.5 Transcriptome Databases: SAGE, ArrayExpress, and GEO *279*
24.2.6 Reference Databases: PubMed, OMIM, and GeneCards *279*
24.2.7 Pathway Databases and Gene Ontology *279*
24.3 Sequence Analysis *280*
24.3.1 Kyte–Doolittle Plot, Helical Wheel Analysis, and Signal Sequence Analysis *280*
24.3.2 Pairwise Alignment *281*
24.3.2.1 Local/Global *281*
24.3.2.2 Optimal/Heuristic *282*
24.3.3 Alignment Statistics *282*
24.3.4 Multiple Alignment *282*
24.4 Evolutionary Bioinformatics *283*
24.4.1 Statistical Models of Evolution *283*
24.4.2 Relation to Score Matrices *284*
24.4.3 Phylogenetic Analysis *285*
24.5 Gene Prediction *285*
24.5.1 Neural Networks or HMMs Based on Hexanucleotide Composition *286*
24.5.2 Comparison with Expressed Sequence Tags or Other Genomes (*Fugu*, Mouse) *286*
24.6 Bioinformatics in Transcriptome and Proteome Analysis *287*
24.6.1 Preprocessing and Normalization *287*
24.6.2 Feature Selection *288*
24.6.3 Similarity Measures: Euclidean Distance, Correlation, Manhattan Distance, Mahalanobis Distance, and Entropy Measures *288*
24.6.4 Unsupervised Learning Procedures: Clustering, Principal Component Analysis, Multidimensional Scaling, and Correspondence Analysis *289*
24.6.5 Supervised Learning Procedures: Linear Discriminant Analysis, Decision Trees, Support Vector Machines, and ANNs *289*
24.6.6 Analysis of Overrepresentation of Functional Categories *290*
24.7 Analysis of Ultraparallel Sequencing Data *291*
24.7.1 Mapping of Ultraparallel Sequencing Data *291*
24.7.2 Genome (Re-)sequencing *292*
24.7.3 Transcriptome Sequencing *292*
24.7.4 ChIP-seq *293*
24.7.5 Epigenetic Analysis *293*
24.7.6 Single-Cell Analysis *294*
24.7.7 Bioethics of Human Sequencing Data *294*
24.8 Bioinformatic Software *294*
Further Reading *295*

25 Drug Research *297*
Manfred Koegl, Ralf Tolle, Ulrich Deuschle, Claus Kremoser, and Michael Wink
25.1 Introduction *297*
25.2 Active Compounds and Their Targets *297*
25.2.1 Identification of Potential Targets in the Human Genome *298*
25.2.2 Comparative Genome Analysis *298*
25.2.3 Experimental Target Identification: *In Vitro* Methods *299*
25.2.4 Experimental Identification of Targets: Model Organisms *300*
25.2.5 Experimental Target Identification in Humans *300*
25.2.6 Difference Between Target Candidates and Genuine Targets *301*
25.2.7 Biologicals *301*
25.2.8 DNA and RNA in New Therapeutic Approaches *302*
25.2.9 Patent Protection for Targets *303*
25.2.10 Compound Libraries as a Source of Drug Discovery *304*
25.2.11 High-Throughput Screening *304*
25.2.12 High-Quality Paramounts in Screening Assays *304*
25.2.13 Virtual Ligand Screening *306*
25.2.14 Activity of Drugs Described in Terms of Efficacy and Potency *307*
25.2.15 Chemical Optimization of Lead Structures *307*
25.3 Preclinical Pharmacology and Toxicology *308*
25.4 Clinical Development *309*
25.5 Clinical Testing *309*
Further Reading *310*

26 Drug Targeting and Prodrugs *311*
Gert Fricker
26.1 Drug Targeting *311*
26.1.1 Passive Targeting by Exploiting Special Physiological Properties of the Target Tissue *311*
26.1.2 Physical Targeting *312*
26.1.3 Active Targeting *313*
26.1.4 Cellular Carrier Systems *316*
26.2 Prodrugs *316*
26.2.1 Prodrugs to Improve Drug Solubility *316*
26.2.2 Prodrugs to Increase Stability *317*
26.3 Penetration of Drugs Through Biological Membranes *317*
26.4 Prodrugs to Extend Duration of Effect *318*
26.5 Prodrugs for the Targeted Release of a Drug *318*
26.6 Prodrugs to Minimize Side Effects *320*
References *320*

27 Molecular Diagnostics in Medicine *323*
Stefan Wölfl and Reinhard Gessner
27.1 Introduction *323*
27.2 Uses of Molecular Diagnostics *323*
27.2.1 Introduction *323*
27.2.2 Monogenic and Polygenic Diseases *323*
27.2.3 Individual Variability in the Genome: Forensics *325*
27.2.4 Individual Variability in the Genome: HLA Typing *325*
27.2.5 Individual Variability in the Genome: Pharmacogenomics *325*
27.2.6 Individual Variability in the Genome: Susceptibility to Infectious Diseases *326*
27.2.7 Viral Diagnosis *326*
27.2.8 Microbial Diagnosis and Resistance Diagnosis *327*
27.3 Which Molecular Variations Should be Detected *327*
27.3.1 Point Mutations *327*

27.3.2 Insertions and Deletions *328*
27.3.3 Nucleotide Repeats *328*
27.3.4 Deletion or Duplication of Genes *328*
27.3.5 Recombination Between Chromosomes *329*
27.3.6 Epigenetic Changes *329*
27.4 Molecular Diagnostic Methods *330*
27.4.1 DNA/RNA Purification *331*
27.4.2 Detection of Target Sequence and Known Sequence Variations *331*
27.4.2.1 Nucleic Acid Tests *331*
27.4.2.2 Quantitative PCR *332*
27.4.2.3 Multiplexing of Nucleic Acid Detection: Nucleic Acid **Microarrays** *333*
27.4.2.4 Production and Manufacture of Microarrays *334*
27.4.2.5 Applications of Fragment Length Analysis *335*
27.4.2.6 Minisequencing *336*
27.4.2.7 Determination of Unknown Mutations *336*
27.5 Outlook *337*
Further Reading *338*
Historic Article: "News & Views" *338*
Reviews *338*
Web Link *338*
Textbooks *338*

28 Recombinant Antibodies and Phage Display *339*
Gustavo Marçal Schmidt Garcia Moreira and Stefan Dübel
28.1 Introduction *339*
28.2 Generation of Specific Recombinant Antibodies *340*
28.2.1 Generation of Antibody Gene Libraries *341*
28.2.2 Selection Systems for Recombinant Antibodies *342*
28.2.2.1 Transgenic Mice with Human IgG Genes *342*
28.2.2.2 *In Vitro* Selection Systems *342*
28.3 Production and Purification of Recombinant Antibodies *348*
28.4 Features and Applications of Recombinant Antibodies *349*
28.4.1 Advantages of Recombinant Antibodies *349*
28.4.2 Formats and Applications of Recombinant Antibodies *350*
28.4.2.1 Camelid Antibodies and V_H Domains *351*
28.4.2.2 scFv and dsFv *351*
28.4.2.3 scFv–Fc Fusions, Fc Engineering, and the Addition of Constant Domains *352*
28.4.2.4 IgG, Fusion Proteins, and Derivatives for Therapy *352*
28.4.2.5 Bispecific Antibodies *354*
28.4.2.6 Chimeric Antigen Receptors (CARs) *355*
28.4.3 The Future of Therapeutic Antibodies *355*
28.4.4 Research and *In Vitro* Diagnostics *356*
28.4.5 Intracellular and Cell-Penetrating Antibodies *356*
28.5 Outlook *357*
Further Reading *357*
Textbooks *357*
References *358*

29 Genetically Modified Mice and Their Impact in Medical Research *361*
Rolf Sprengel and Mazahir T. Hasan
29.1 Overview *361*
29.2 Transgenic Mice *362*
29.2.1 Retroviral Infection *362*
29.2.2 Pronuclear Injection *363*

29.3 Homologous Recombination: Knockout (Knock-In) Mice *364*
29.4 Endonuclease-Based Knockout Mice *366*
29.5 Endonuclease-Based Knock-In Mice *367*
29.6 Conditionally Regulated Gene Expression *367*
29.7 Gene Transfer to Subpopulations of Cells *368*
29.7.1 Electroporation of Mouse Embryos (Plasmid DNA) *368*
29.7.2 Virus-Mediated Gene Transfer (Lentivirus, rAAVs) *369*
29.7.3 Virus-Mediated Gene Deletion (Cre/lox) *370*
29.7.4 Virus-Mediated Gene Knockdown (shRNA, Antagomirs) *370*
29.8 Impact of Genetically Modified Mice in Biomedicine *370*
29.8.1 Alzheimer's Disease *370*
29.8.2 Amyotrophic Lateral Sclerosis (ALS) *370*
29.8.3 Psychological and Cognitive Disorders *371*
29.8.4 Autism Spectrum Disorder (ASD) *371*
29.8.5 Chemogenetics, Optogenetics, and Magnetogenetics *372*
29.9 Outlook *372*
Reference *373*
Further Reading *373*

30 Plant Biotechnology *375*
Helke Hillebrand and Rüdiger Hell
30.1 Introduction *375*
30.1.1 Green Genetic Engineering: A New Method Toward Traditional Goals *375*
30.1.2 Challenges in Plant Biotechnology *376*
30.2 Gene Expression Control and Genome Editing *376*
30.2.1 Gene Expression Control *377*
30.2.2 Genome Editing *377*
30.3 Production of Transgenic Plants *378*
30.3.1 Transformation Systems *379*
30.3.1.1 *Agrobacterium* as a Natural Transformation System *379*
30.3.1.2 Biolistic Method: Gene Gun *381*
30.3.1.3 Plastid Transformation *382*
30.3.1.4 Viral Systems *382*
30.4 Selection of Transformed Plant Cells *383*
30.4.1 Requirements for an Optimal Selection Marker System *383*
30.4.2 Negative Selection Marker Systems *384*
30.4.3 Positive Selection Marker Systems *385*
30.4.4 Selection Systems, Genetic Engineering Safety, and Marker-Free Plants *385*
30.5 Regeneration of Transgenic Plants *387*
30.5.1 Regeneration Procedures *387*
30.5.2 Composition of Regeneration Media *387*
30.6 Plant Analysis: Identification and Characterization of Genetically Engineered Plants *388*
30.6.1 DNA and RNA Verification *388*
30.6.2 Protein Analysis *389*
30.6.3 Genetic and Molecular Maps *389*
30.6.4 Stability of Transgenic Plants *390*
Further Reading *390*

31 Biocatalysis in the Chemical Industry *393*
Michael Breuer and Bernhard Hauer
31.1 Introduction *393*
31.2 Bioconversion/Enzymatic Procedures *395*
31.3 Development of an Enzyme for Industrial Biocatalysis *397*
31.3.1 Identification of Novel Biocatalysts *397*

31.3.2 Improvement of Biocatalysts *399*
31.3.3 Production of Biocatalysts *399*
31.3.4 Outlook *399*
31.3.5 Case Study 1: Screening for New Nitrilases *400*
31.3.6 Case Study 2: Use of Known Enzymes for New Reactions: Lipases for the Production of Optically Active Amines and Alcohols *400*
31.3.7 Case Study 3: Enzyme Optimization with Rational and Evolutive Methods *401*
31.4 Fermentative Procedures *402*
31.4.1 Improvement of Fermentation Processes *402*
31.4.2 Classical Strain Optimization *403*
31.4.3 Metabolic Engineering *404*
31.4.4 Case Study 4: Fermentative Production of *n*-Butanol *405*
31.4.5 Case Study 5: Production of Glutamic Acid with *C. glutamicum* *406*
31.4.5.1 Molecular Mechanism of Glutamate Overproduction *406*
31.4.6 Case Study 6: Production of Lysine with *C. glutamicum* *407*
31.4.6.1 Molecular Mechanism of Lysine Biosynthesis *407*
31.4.6.2 Deregulation of the Key Enzyme Aspartate Kinase *408*
31.4.7 Genomic Research and Functional Genomics *409*
31.4.8 Case Study 7: Fermentative Penicillin Production *409*
31.4.9 Case Study 8: Vitamin B_2 Production *409*
31.4.9.1 Riboflavin Biosynthesis *410*
31.4.9.2 Classical Strain Development *410*
References *410*

Part IV Biotechnology in Industry *411*

32 Industrial Application: Biotech Industry, Markets, and Opportunities *413*
Julia Schüler
32.1 Historical Overview and Definitions of Concepts *413*
32.2 Areas of Industrial Application of Molecular Biotechnology *414*
32.2.1 Red Biotechnology *414*
32.2.1.1 Biopharmaceutical Drug Development *414*
32.2.1.2 Gene and Cell Therapy *416*
32.2.1.3 Tissue Engineering/Regenerative Medicine *419*
32.2.1.4 Pharmacogenomics and Personalized Medicine *421*
32.2.1.5 Molecular Diagnostic Agents *421*
32.2.1.6 Systems Biology *422*
32.2.1.7 Synthetic Biology *422*
32.2.2 Green Biotechnology *422*
32.2.2.1 Transgenic Plants *422*
32.2.2.2 Genomic Approaches in Green Biotechnology *423*
32.2.2.3 Novel Food and Functional Food *423*
32.2.2.4 Livestock Breeding *423*
32.2.3 White Biotechnology *424*
32.3 Status Quo of the Biotech Industry Worldwide *424*
32.3.1 Global Overview *424*
32.3.2 United States *424*
32.3.3 Europe *424*

33 Patents in the Molecular Biotechnology Industry: Legal and Ethical Issues *425*
David Resnik
33.1 Patent Law *425*
33.1.1 What is a Patent? *425*

33.1.2 How Does One Obtain a Patent? *426*
33.1.3 What is the Proper Subject Matter for a Patent? *426*
33.1.4 Types of Patents in Pharmaceutical and Molecular Biotechnology *427*
33.1.5 Patent Infringement *427*
33.1.6 International Patent Law *428*
33.2 Ethical and Policy Issues in Biotechnology Patents *428*
33.2.1 No Patents on Nature *428*
33.2.2 Threats to Human Dignity *429*
33.2.3 Problems with Access to Technology *430*
33.2.4 Benefit Sharing *432*
33.3 Conclusions *433*
Acknowledgments *433*

34 Drug Approval in the European Union and United States *435*
Gary Walsh
34.1 Introduction *435*
34.2 Regulation Within the European Union *435*
34.2.1 The EU Regulatory Framework *435*
34.2.2 The EMA and National Competent Authorities *436*
34.2.3 New Drug Approval Routes *437*
34.2.3.1 The Centralized Procedure *437*
34.2.3.2 Decentralized Procedure and Mutual Recognition *438*
34.3 Regulation in the United States *438*
34.3.1 CDER and CBER *439*
34.3.2 The Approvals Procedure *439*
34.4 The Advent and Regulation of Biosimilars *440*
34.5 International Regulatory Harmonization *441*
References *442*

35 Emergence of a Biotechnology Industry *445*
Claus Kremoser
Reference *451*
Further Reading *451*

36 The 101 of Founding a Biotech Company *453*
Claus Kremoser and Michael Wink
36.1 First Steps Toward Your Own Company *453*
36.2 Employees: Recruitment, Remuneration, and Participation *456*

37 Marketing *459*
Claus Kremoser and Michael Wink
37.1 Introduction *459*
37.2 What Types of Deals Are Possible? *460*
37.3 What Milestone or License Fees Are Effectively Paid in a Biotech/Pharma Cooperation? *460*
37.4 PR and IR in Biotech Companies *461*
Further Reading *462*
Websites *462*

Glossary *463*

Index *491*